XRTXHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 1 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores XORTX Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (17): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own XORTX Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on XRTX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Of the 8 most recent actions, 3 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Jan 2024 | Alliance Global Partners | Maintains | Buy | $9.00 → $14 |
| 22 Dec 2021 | Alliance Global Partners | Initiates | Buy | — |
| 9 Dec 2021 | Alliance Global Partners | Initiates | Buy | — |
| 3 Oct 2012 | Cantor Fitzgerald | Maintains | Hold | $11 → $8.50 |
| 28 Sept 2012 | Cantor Fitzgerald | Maintains | Hold | $12 → $11 |
| 6 July 2012 | BMO Capital | Maintains | Market Perform | $15 → $12 |
| 30 Mar 2012 | Brean Capital | Maintains | Buy | $18 → $20 |
| 23 Mar 2012 | BMO Capital | Maintains | Market Perform | $13 → $15 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 63% of US stocks
Cheaper than 41% of US stocks
Cheaper than 68% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XRTX appears on the weeks it earns a place.
XORTX Therapeutics announced that board director Anthony Giovinazzo is resigning for personal reasons and to pursue other interests. The company expressed appreciation for his contributions.
Why it matters — A director resignation can signal a change in board composition and governance, which shareholders may monitor for any impact on company oversight.
XORTX Therapeutics announced the appointment of Depesh Narotam as an independent director to its board of directors. Narotam brings over 20 years of experience in the financial services industry.
Why it matters — Adding a seasoned financial services professional to the board as an independent director could bring valuable financial expertise and governance perspective to the company.
Of the 1 analysts covering XORTX Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks XORTX Therapeutics, Inc. 22 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, XORTX Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No analyst covering XORTX Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XRTX are extrapolating price history, which says nothing about the business.
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company dedicated to developing innovative therapies that target aberrant purine metabolism and xanthine oxidase to lower uric acid levels and treat gout and progressive kidney diseases.
The most recent item we track (GlobeNewsWire, 31 July 2026): "XORTX Announces Director Resignation". XORTX Therapeutics announced that board director Anthony Giovinazzo is resigning for personal reasons and to pursue other interests. The company expressed appreciation for his contributions.
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company dedicated to developing innovative therapies that target aberrant purine metabolism and xanthine oxidase to lower uric acid levels and treat gout and progressive kidney diseases. Its pipeline includes the lead XRx-026 program, advancing toward new drug application filing for gout treatment; XRx-008 in phase two for autosomal dominant polycystic kidney disease; XRx-101 in phase two for acute kidney injury and organ damage linked to respiratory virus infections; and preclinical XRx-225 for type 2 diabetic nephropathy. These programs address unmet needs in metabolic and renal disorders by modulating uric acid production. XORTX Therapeutics Inc. focuses on improving patient quality of life through first-in-class uric acid lowering agents for rare and chronic kidney conditions. Founded in 2009 and headquartered in Calgary, Alberta, the company advances these therapies through clinical development stages, emphasizing precision medicine approaches in the biopharmaceutical sector.
CEO Dr. Allen Warren Davidoff Ph.D. · 2 employees · Canada · https://www.xortx.com